Pharmaceutical News

RSS

Mylan launches Famciclovir Tablets

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Famciclovir Tablets, 125 mg, 250 mg and 500 mg, the generic version of Novartis' Famvir® Tablets, a treatment for herpes.

20 Apr 2011

Adeona, TG United enter commercial-scale manufacturing agreement for reaZin

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it has executed an agreement with TG United, Inc. of Brooksville, Florida, to provide commercial-scale manufacturing capabilities for reaZin. Adeona is developing reaZin, its product candidate for the dietary management of Alzheimer's disease and mild cognitive impairment, as a prescription medical food.

20 Apr 2011

Forest acquires worldwide rights to novel antiarrhythmic agent azimilide

Forest Laboratories, Inc. today announced that its wholly-owned subsidiary Forest Laboratories Holdings Limited and Blue Ash Therapeutics, LLC have entered into an asset purchase agreement, pursuant to which Forest has acquired worldwide rights to azimilide, a novel antiarrhythmic agent originally developed by Procter & Gamble Pharmaceuticals.

20 Apr 2011

Study demonstrates clinical effectiveness of Systagenix ADAPTIC TOUCH as a primary wound contact layer

Systagenix announced on 20 April 2011 that a recent product evaluation published in the journal Wounds UK, Vol 7, No 1, demonstrates the clinical effectiveness of ADAPTIC TOUCH® as a primary wound contact layer that addresses the needs of both patients and healthcare professionals.

20 Apr 2011

Covidien supports FDA’s REMS for important class of pain medications

Covidien (NYSE: COV), a leading global provider of healthcare products, supports the U.S. Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) for an important class of pain medications.

20 Apr 2011

Rituxan receives FDA approval for treating two rare diseases

The U.S. Food and Drug Administration today approved Rituxan (rituximab), in combination with glucocorticoids (steroids), to treat patients with Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA), two rare disorders that cause blood vessel inflammation (vasculitis).

20 Apr 2011

TCI forecasts cancer vaccine market to approach $3 billion in 2015

Technology Catalysts International (TCI), leading global consultants to the pharmaceutical industry, announced that research on cancer trends and development has identified cancer vaccines as a viable treatment option for a variety of cancers that currently have ineffective treatments. The potential of the cancer vaccine market is forecast to approach $3 billion in 2015.

20 Apr 2011

Breakdown products of thalidomide cause birth defects: New study

Thalidomide may have been withdrawn in the early 1960s for use by pregnant women, but its dramatic effects remain memorable half a century later. Now, researchers have taken a major step toward understanding exactly how thalidomide causes the birth defects.

20 Apr 2011

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

Genentech, a member of the Roche Group and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab), in combination with corticosteroids, as a new medicine for adults with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA).

20 Apr 2011

Plans to combat painkiller abuse

This Tuesday, the Obama administration announced a plan to fight prescription drug abuse, warning that accidental fatal overdoses now exceed the combined deadly overdoses from the crack epidemic of the 1980s and black tar heroin in the 1970s.

19 Apr 2011

EMA CHMP grants positive opinion for Biogen Idec's AVONEX PEN

Biogen Idec announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of AVONEX® PEN™ for patients with relapsing multiple sclerosis (MS) and patients with a single demyelinating event.

19 Apr 2011

SafeMinds calls for immediate vaccine safety studies in autistic children

Alison MacNeil issued the following statements today regarding vaccines.

19 Apr 2011

Cumberland acquires Vanderbilt's ifetroban rights

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it has entered into an agreement to acquire the rights to ifetroban, a new Phase II development product.

19 Apr 2011

AADSM event to discuss latest advances in sleep-disordered breathing research

Nearly 800 dental sleep medicine professionals from around the world will gather at the 20th Anniversary Meeting of the American Academy of Dental Sleep Medicine, which will take place Saturday, June 11, 2011, at the Hilton Minneapolis in Minneapolis, Minn.

19 Apr 2011

Canada needs to modernize its pharmaceutical laws to ensure drug safety: CMAJ

Canada needs to modernize its pharmaceutical drug laws to ensure that new drugs as well as older drugs are safe for Canadians, states an editorial in CMAJ.

19 Apr 2011

Seattle enters second ADC research collaboration agreement with Genmab

Genmab A/S and Seattle Genetics, Inc. announced today that the companies have entered into a second antibody-drug conjugate research collaboration agreement.

19 Apr 2011

BioSante, Aduro BioTech enter license agreement for GVAX cancer vaccines

Aduro BioTech, a clinical-stage immunotherapy company, has licensed GVAX Pancreas Cancer Vaccine and GVAX Prostate Cancer Vaccine BioSante Pharmaceuticals, Inc. in exchange for milestone and royalty payments after commercialization.

19 Apr 2011

BioSante licenses Pancreas and Prostate cancer vaccines to Aduro BioTech

BioSante Pharmaceuticals, Inc. today announced it has licensed its Pancreas Cancer Vaccine and Prostate Cancer Vaccine to Aduro BioTech, a clinical-stage immunotherapy company, solely for use in combination with Aduro's proprietary vaccine platform based on Listeria monocytogenes (Lm).

19 Apr 2011

Bedford Labs launches cancer drug Topotecan Hydrochloride for Injection

Bedford Laboratories, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Topotecan Hydrochloride for Injection, 4 mg (base)/vial to its diverse portfolio. Topotecan is AP Bioequivalent to the reference listed drug Hycamtin® (topotecan HCl) for injection by GlaxoSmithKline.

19 Apr 2011

Drospirenone doesn't carry any risk of gall bladder disease

Drospirenone, the top-selling oral contraceptive marketed as Yaz or Yasmin in the U.S. and Canada, doesn't carry any more risk of gall bladder disease than the older generation of birth control pills, despite claims by some consumers and lawyers in both countries, according to a new study by University of British Columbia and Vancouver Coastal Health Research Institute researcher Mahyar Etminan.

19 Apr 2011